FDA Supports Intravenous Brexanolone for Postpartum Depression
In 2015, we first reported on SAGE-547 (SAGE Therapeutics), a new medication for the treatment of postpartum depression (PPD). SAGE-547, now called brexanolone, is an allosteric modulator of GABAA receptors. Since that time, Sage Therapeutics has conducted three randomized controlled trials, enrolling a total of 247 women diagnosed with moderate to severe postpartum depression. This… Read More »